Kebin Cheng

Kebin Cheng

Auto-generated profile, based on publicly available information

Kebin Cheng

Department of Pulmonary and Critical Care Medicine, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 April 2024 in Cancer Letters
Verified
Journal Article
Closed access
JLJie Luo
Jie Luo
KCKebin Cheng
Kebin Cheng
XJXianxiu Ji
Xianxiu Ji
CGCaixia Gao
Caixia Gao
RZRen Zhu
Ren Zhu
QXQingqiang Xu
Qingqiang Xu

3 July 2021 in Critical Care
Verified
Journal Article
Open access
PDF file
RHRunzhi Huang
Runzhi Huang
TMTong Meng
Tong Meng
QZQiongfang Zha
Qiongfang Zha
KCKebin Cheng
Kebin Cheng
XZXin Zhou
Xin Zhou
RLRuilin Liu
Ruilin Liu
Background: The coronavirus disease 2019 (COVID-19) has induced a worldwide epidemiological event with a high infectivity and mortality. However, the predicting biomarkers and their potential mechanism in the progression of COVID-19 are not well known. Objective: The aim of this study is to identify the candidate predictors of COVID-19 and investigate their underlying mechanism. Methods: The retrospective study was conducted to identify the potential laboratory indicators with prognostic values of COVID-19 disease. Then, the prognostic nomogram was constructed to predict the overall survival of COVID-19 patients. Additionally, the scRNA-seq data of BALF and PBMCs from COVID-19 patients were downloaded to investigate the underlying mechanism of the most important prognostic indicators in lungs and peripherals, respectively. Results: In total, 304 hospitalized adult COVID-19 patients in Wuhan Jinyintan Hospital were included in the retrospective study. CEA was the only laboratory indicator with significant difference in the univariate (P < 0.001) and multivariate analysis (P = 0.020). The scRNA-seq data of BALF and PBMCs from COVID-19 patients were downloaded to investigate the underlying mechanism of CEA in lungs and peripherals, respectively. The results revealed the potential roles of CEA were significantly distributed in type II pneumocytes of BALF and developing neutrophils of PBMCs, participating in the progression of COVID-19 by regulating the cell–cell communication. Conclusion: This study identifies the prognostic roles of CEA in COVID-19 patients and implies the potential roles of CEACAM8-CEACAM6 in the progression of COVID-19 by regulating the cell–cell communication of developing neutrophils and type II pneumocyte.

18 December 2024 in Journal of Pharmaceutical Health Care and Sciences
Verified
Journal Article
Open access
PDF file
YHYifan Hong
Yifan Hong
KCKebin Cheng
Kebin Cheng
HQHan Qu
Han Qu
YWYuting Wang
Yuting Wang
YWYuanyuan Wang
Yuanyuan Wang
ZWZhenghua Wu
Zhenghua Wu
Background: Oncolytic virus therapy is a rapidly evolving emerging approach for the medical management of cancer. Talimogene laherparepvec (T-VEC) is the first and only Food and Drug Administration (FDA)-approved oncolytic virus therapy. Considering that exactly how T-VEC works is not known, there is a strong need for a comprehensive pharmacovigilance study to identify safety signals of potential risks with T-VEC. Objective: The objective of this study was to assess the risk of adverse events (AEs) related to T-VEC. Methods: We implemented a pharmacovigilance study utilizing individual case safety reports (ICSRs) reported to the FDA Adverse Event Reporting System (FAERS) database dated from 2004 quarter 1 to 2023 quarter 3. In this study, we used two algorithms, reporting odds ratio (ROR) and information component (IC), to assess the risk of AEs related to T-VEC. Results: A total of 1138 ICSRs of patients who received the T-VEC and reported to the FDA dated from 2004 quarter 1 to 2023 quarter 3 were available. A total of seven system organ classes (SOCs) demonstrated statistically significant signals, i.e. General disorders and administration site conditions, Injury, poisoning and procedural complication, Infections and infestations, Neoplasms benign, malignant and unspecified, Skin and subcutaneous tissue disorders, Hepatobiliary disorders, and Endocrine disorders. From the preferred term level perspective, the most reported AEs in T-VEC-treated patients were pyrexia, illness, influenza, influenza-like illness, and chills. Unexpected significant AEs were detected, such as sepsis, encephalitis, syncope, and lymphadenopathy. Conclusions: Most AEs in T-VEC-treated patients have been previously mentioned in the prescriptive information or documented in other clinical trials. But safety signals were also be detected in 4 unexpected AEs (sepsis, encephalitis, syncope, and lymphadenopathy). Further clinical trials need to be undertaken to facilitate a more comprehensive comprehension of the safety profile of T-VEC.

2 April 2022 in BMC Pulmonary Medicine
Verified
Journal Article
Open access
PDF file
XCXianqiu Chen
Xianqiu Chen
JLJie Luo
Jie Luo
LYLi Yang
Li Yang
LHLikun Hou
Likun Hou
BJBing Jie
Bing Jie
KCKebin Cheng
Kebin Cheng
Background: The etiology of interstitial lung diseases (ILDs) is varied. Early diagnosis and a specific pathological type could significantly improve the prognosis. Mostly, it is difficult to make the etiology diagnosis of ILD through traditional biopsy methods. It will be of great significance to explore an effective biopsy method. Methods: The prospective study was designed to evaluate the diagnostic value of transbronchial lung cryobiopsy (TBCB) combined with rapid on-site evaluation (ROSE), compared with conventional transbronchial lung biopsy (TBLB), in a large sample of ILD patients. All patients enrolled will undergo both TBLB and TBCB procedures. The study will observe the differences in the diagnostic efficiency of pathological typing and incidence of operation-related complications between TBCB and TBLB. Besides, it will analyze the relationship between the time of biopsy and the incidence of complications, the relationship between freezing time, size of specimen, and complications. And it will evaluate the consistency of pathological, clinical, and radiology. Discussion: It may be the first time that ROSE technique will be used in the diagnosis of ILD. The results of this study will clarify the value of TBCB in the diagnosis of ILD and confirm its safety and effectiveness, which is expected to significantly improve the efficiency of diagnosis in ILD patients. Trail registration: The trial was registered on the Chinese Clinical Trial Registry website (http://www.chictr.org.cn/showproj.aspx?proj=57834) (Registration number: ChiCTR2000035492).

22 January 2025 in BMC Cancer
Verified
Journal Article
Open access
PDF file
HYHeng Yang
Heng Yang
MLMan-Hui Li
Man-Hui Li
QLQiu-Hong Li
Qiu-Hong Li
KCKe-Bin Cheng
Ke-Bin Cheng
WCWei-Jun Cao
Wei-Jun Cao
Primary pulmonary Mucosa-associated lymphoid tissue (MALT) lymphoma is a sporadic disease with a favorable prognosis. Particularly, pulmonary MALT lymphoma coexisting with lung cancer is not only rare but also prone to misdiagnosis. The clinical characteristics and prognostic factors of this co-occurrence, however, remain poorly understood. We retrospectively analyzed the clinical, imaging, genetic mutations and pathological data among adult patients with pulmonary MALT lymphoma coexisting with lung cancer who were confirmed by pathological examinations after operation at Shanghai Pulmonary Hospital between 1st January 2013 and 31st May 2024. After exclusions, a total of 14 patients were included in the study, of which eleven patients were women and only 3 were men, with a median age of 57 [IQR: 53–67] years. Pulmonary MALT lymphoma presented a median diameter of 14 mm (IQR: 6–23). Nodule was the most frequent CT feature and existing pattern of pulmonary lesions (n = 8). The lung cancer was with a median diameter of 10.7 [IQR:6,20] mm, with nodules as the predominant CT feature (n = 12). Six patients manifested dual primary malignancies within the same lung lobe, termed collision tumors, whereas the remaining eight had lesions in different lobes. Five cases exhibited EGFR mutant, and one case showed no mutation. 13 patients were pathological confirmed with lung adenocarcinoma and one with microcarcinoma. Postoperatively, all-cause mortality rate was low, indicating a positive prognosis. One patient died 41 months after surgery due to a pulmonary infection, while the remaining 13 patients were in good condition with an average follow-up of 37.92 months. In patients with pulmonary lesions, particularly multiple lesions, comprehensive preoperative evaluation is crucial to prevent misdiagnosis or missed diagnoses. Besides, surgical resection is desirable when both lung cancer and MALT are at an early stage and can be resected with minimally invasive surgery (minimally lung resection). We retrospectively analyzed the clinical presentation, imaging, genetic mutations and pathological data among adult patients with pulmonary MALT lymphoma coexisting with lung cancer. This is the largest collection of clinical information for MALT patients with lung cancer, including 14 patients. Most patients survived for three years postoperatively, indicating a positive prognosis. Due to the relative rarity of these cases, we assessed follow-up after surgery alone and did not evaluate the outcomes of other treatments.